Symbols / GLSI
GLSI Chart
About
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company also develops FLAMINGO-01, which is in Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 348.86M |
| Enterprise Value | 340.89M | Income | -19.48M | Sales | — |
| Book/sh | 0.16 | Cash/sh | 0.28 | Dividend Yield | — |
| Payout | 0.00% | Employees | 4 | IPO | — |
| P/E | — | Forward P/E | -30.71 | PEG | — |
| P/S | — | P/B | 159.37 | P/C | — |
| EV/EBITDA | -17.41 | EV/Sales | — | Quick Ratio | 2.35 |
| Current Ratio | 2.35 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.46 | EPS next Y | -0.82 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-31 | ROA | -254.19% |
| ROE | -5.43% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 13.85M |
| Shs Float | 6.57M | Short Float | 19.21% | Short Ratio | 1.70 |
| Short Interest | — | 52W High | 34.10 | 52W Low | 7.78 |
| Beta | 1.49 | Avg Volume | 549.99K | Volume | 65.44K |
| Target Price | $47.50 | Recom | None | Prev Close | $24.88 |
| Price | $25.18 | Change | 1.21% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$47.50
Mean price target
2. Current target
$25.18
Latest analyst target
3. DCF / Fair value
$-1.76
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$25.18
Low
$45.00
High
$50.00
Mean
$47.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-30 | main | HC Wainwright & Co. | Buy → Buy | $50 |
| 2025-04-21 | main | HC Wainwright & Co. | Buy → Buy | $39 |
| 2025-02-11 | reit | HC Wainwright & Co. | Buy → Buy | $38 |
| 2024-08-23 | main | HC Wainwright & Co. | Buy → Buy | $38 |
| 2024-05-22 | reit | HC Wainwright & Co. | Buy → Buy | $36 |
| 2024-02-28 | reit | HC Wainwright & Co. | Buy → Buy | $36 |
| 2024-02-20 | main | HC Wainwright & Co. | Buy → Buy | $36 |
| 2023-04-10 | reit | HC Wainwright & Co. | — → Buy | $38 |
| 2021-09-01 | init | HC Wainwright & Co. | — → Buy | $78 |
| 2021-01-27 | init | Aegis Capital | — → Buy | $75 |
| 2021-01-26 | init | Aegis Capital | — → Buy | $75 |
- Understanding Momentum Shifts in (GLSI) - Stock Traders Daily Wed, 25 Feb 2026 03
- Greenwich lands 2 AACR 2026 slots, first with FLAMINGO-01 Steering Committee - Stock Titan ue, 24 Feb 2026 11
- Greenwich LifeSciences, Inc. Announces Acceptance of Two Abstracts for Presentation at AACR Annual Meeting 2026 on Breast Cancer Immunotherapy GLSI-100 - Quiver Quantitative ue, 24 Feb 2026 11
- Why is GLSI stock rising today? - MSN Mon, 15 Dec 2025 12
- Why Is GLSI Stock Rising Today? - Stocktwits Mon, 15 Dec 2025 08
- GLSI Should I Buy - Intellectia AI Fri, 20 Feb 2026 04
- Greenwich LifeSciences CEO Patel buys $53,694 in GLSI stock - Investing.com hu, 15 Jan 2026 08
- $GLSI stock is down 15% today. Here's what we see in our data. - Quiver Quantitative ue, 03 Feb 2026 08
- Greenwich LifeSciences (Nasdaq: GLSI) sees ~80% recurrence cut in 250-patient FLAMINGO-01 arm - Stock Titan Mon, 15 Dec 2025 08
- GLSI Stock Surges Pre-Market On Clearing FDA Manufacturing Step For Its Breast Cancer Trial - Stocktwits hu, 22 Jan 2026 11
- Patel, Greenwich Lifesciences CEO, buys $63k in GLSI stock By Investing.com - Investing.com Nigeria Sun, 01 Feb 2026 08
- Greenwich LifeSciences (Nasdaq: GLSI) finishes 250-patient arm, targets 88,000 eligible - Stock Titan Mon, 08 Dec 2025 08
- Insider Purchase: CEO and CFO of $GLSI Buys 2,300 Shares | GLSI Stock News - Quiver Quantitative ue, 04 Nov 2025 08
- $GLSI stock is down 11% today. Here's what we see in our data. - Quiver Quantitative Fri, 02 Jan 2026 08
- Biotech Greenwich LifeSciences raises $7M in 3 weeks for breast cancer trial - Stock Titan ue, 27 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1800 | 53694 | — | Purchase at price 29.83 per share. | PATEL SNEHAL | Chief Executive Officer | — | 2026-01-13 00:00:00 | D |
| 1 | 2900 | 79866 | — | Purchase at price 27.54 per share. | PATEL SNEHAL | Chief Executive Officer | — | 2026-01-12 00:00:00 | D |
| 2 | 4300 | 91848 | — | Purchase at price 21.36 per share. | PATEL SNEHAL | Chief Executive Officer | — | 2025-12-31 00:00:00 | D |
| 3 | 2900 | 63017 | — | Purchase at price 21.73 per share. | PATEL SNEHAL | Chief Executive Officer | — | 2025-12-30 00:00:00 | D |
| 4 | 4100 | 51742 | — | Purchase at price 12.62 per share. | PATEL SNEHAL | Chief Executive Officer | — | 2025-12-18 00:00:00 | D |
| 5 | 4600 | 38502 | — | Purchase at price 8.37 per share. | PATEL SNEHAL | Chief Executive Officer | — | 2025-11-25 00:00:00 | D |
| 6 | 10600 | 89358 | — | Purchase at price 8.43 per share. | PATEL SNEHAL | Chief Executive Officer | — | 2025-11-07 00:00:00 | D |
| 7 | 2300 | 21298 | — | Purchase at price 9.26 per share. | PATEL SNEHAL | Chief Executive Officer | — | 2025-10-31 00:00:00 | D |
| 8 | 3600 | 35568 | — | Purchase at price 9.88 per share. | PATEL SNEHAL | Chief Executive Officer | — | 2025-04-25 00:00:00 | D |
| 9 | 5400 | 48492 | — | Purchase at price 8.98 per share. | PATEL SNEHAL | Chief Executive Officer | — | 2025-04-17 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -16.01M | -9.32M | -8.04M | -4.59M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -15.79M | -8.89M | -7.83M | -4.57M |
| ReconciledDepreciation | 3.61K | 3.61K | 3.61K | 3.61K |
| EBITDA | -16.01M | -9.32M | -8.04M | -4.59M |
| EBIT | -16.01M | -9.33M | -8.04M | -4.60M |
| NetInterestIncome | 223.01K | 436.06K | 215.02K | 27.37K |
| InterestIncome | 223.01K | 436.06K | 215.02K | 27.37K |
| NormalizedIncome | -15.79M | -8.89M | -7.83M | -4.57M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -15.79M | -8.89M | -7.83M | -4.57M |
| TotalExpenses | 16.01M | 9.33M | 8.04M | 4.60M |
| TotalOperatingIncomeAsReported | -16.01M | -9.33M | -8.04M | -4.60M |
| DilutedAverageShares | 13.01M | 12.85M | 12.91M | 12.94M |
| BasicAverageShares | 13.01M | 12.85M | 12.91M | 12.94M |
| DilutedEPS | -1.21 | -0.69 | -0.61 | -0.35 |
| BasicEPS | -1.21 | -0.69 | -0.61 | -0.35 |
| DilutedNIAvailtoComStockholders | -15.79M | -8.89M | -7.83M | -4.57M |
| NetIncomeCommonStockholders | -15.79M | -8.89M | -7.83M | -4.57M |
| NetIncome | -15.79M | -8.89M | -7.83M | -4.57M |
| NetIncomeIncludingNoncontrollingInterests | -15.79M | -8.89M | -7.83M | -4.57M |
| NetIncomeContinuousOperations | -15.79M | -8.89M | -7.83M | -4.57M |
| PretaxIncome | -15.79M | -8.89M | -7.83M | -4.57M |
| NetNonOperatingInterestIncomeExpense | 223.01K | 436.06K | 215.02K | 27.37K |
| InterestIncomeNonOperating | 223.01K | 436.06K | 215.02K | 27.37K |
| OperatingIncome | -16.01M | -9.33M | -8.04M | -4.60M |
| OperatingExpense | 16.01M | 9.33M | 8.04M | 4.60M |
| ResearchAndDevelopment | 12.95M | 7.70M | 6.48M | 3.56M |
| SellingGeneralAndAdministration | 3.06M | 1.63M | 1.56M | 1.04M |
| GeneralAndAdministrativeExpense | 3.06M | 1.63M | 1.56M | 1.04M |
| OtherGandA | 3.06M | 1.63M | 1.56M | 1.04M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 13.15M | 12.85M | 12.85M | 13.15M |
| ShareIssued | 13.15M | 12.85M | 12.85M | 13.15M |
| TangibleBookValue | 2.53M | 6.70M | 13.21M | 26.82M |
| InvestedCapital | 2.53M | 6.70M | 13.21M | 26.83M |
| WorkingCapital | 2.53M | 6.70M | 13.21M | 26.82M |
| NetTangibleAssets | 2.53M | 6.70M | 13.21M | 26.82M |
| CommonStockEquity | 2.53M | 6.70M | 13.21M | 26.83M |
| TotalCapitalization | 2.53M | 6.70M | 13.21M | 26.83M |
| TotalEquityGrossMinorityInterest | 2.53M | 6.70M | 13.21M | 26.83M |
| StockholdersEquity | 2.53M | 6.70M | 13.21M | 26.83M |
| RetainedEarnings | -66.15M | -50.36M | -41.47M | -33.65M |
| AdditionalPaidInCapital | 68.67M | 57.05M | 54.67M | 60.47M |
| CapitalStock | 13.15K | 12.85K | 12.85K | 13.15K |
| CommonStock | 13.15K | 12.85K | 12.85K | 13.15K |
| TotalLiabilitiesNetMinorityInterest | 1.56M | 294.41K | 262.90K | 385.17K |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentLiabilities | 1.56M | 294.41K | 262.90K | 385.17K |
| CurrentDeferredLiabilities | 306.28K | |||
| PayablesAndAccruedExpenses | 1.25M | 294.41K | 262.90K | 385.17K |
| CurrentAccruedExpenses | 75.92K | 38.09K | 42.06K | 164.33K |
| InterestPayable | 220.84K | 220.84K | ||
| Payables | 1.18M | 256.32K | 220.84K | 220.84K |
| DuetoRelatedPartiesCurrent | 0.00 | |||
| AccountsPayable | 1.18M | 256.32K | 220.84K | 220.84K |
| TotalAssets | 4.09M | 6.99M | 13.48M | 27.22M |
| TotalNonCurrentAssets | 1.78K | 5.39K | 9.00K | 12.62K |
| GoodwillAndOtherIntangibleAssets | 1.78K | 5.39K | 9.00K | 12.62K |
| OtherIntangibleAssets | 1.78K | 5.39K | 9.00K | 12.62K |
| CurrentAssets | 4.09M | 6.99M | 13.47M | 27.20M |
| CashCashEquivalentsAndShortTermInvestments | 4.09M | 6.99M | 13.47M | 27.20M |
| CashAndCashEquivalents | 4.09M | 6.99M | 13.47M | 27.20M |
| CashFinancial | 4.09M | 6.99M | 13.47M | 27.20M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -7.27M | -6.48M | -6.20M | -4.29M |
| RepurchaseOfCapitalStock | 0.00 | -7.54M | 0.00 | |
| IssuanceOfCapitalStock | 4.37M | 0.00 | 3.11M | |
| EndCashPosition | 4.09M | 6.99M | 13.47M | 27.20M |
| BeginningCashPosition | 6.99M | 13.47M | 27.20M | 28.66M |
| ChangesInCash | -2.90M | -6.48M | -13.74M | -1.46M |
| FinancingCashFlow | 4.37M | 0.00 | -7.54M | 2.84M |
| CashFlowFromContinuingFinancingActivities | 4.37M | 0.00 | -7.54M | 2.84M |
| NetOtherFinancingCharges | -275.15K | |||
| ProceedsFromStockOptionExercised | 0.00 | 3.11M | ||
| NetCommonStockIssuance | 4.37M | 0.00 | -7.54M | 0.00 |
| CommonStockPayments | 0.00 | -7.54M | 0.00 | |
| CommonStockIssuance | 4.37M | 0.00 | 3.11M | |
| OperatingCashFlow | -7.27M | -6.48M | -6.20M | -4.29M |
| CashFlowFromContinuingOperatingActivities | -7.27M | -6.48M | -6.20M | -4.29M |
| ChangeInWorkingCapital | 1.27M | 31.50K | -122.27K | -385.17K |
| ChangeInOtherWorkingCapital | 306.28K | |||
| ChangeInPayablesAndAccruedExpense | 959.05K | 31.50K | -122.27K | -385.17K |
| ChangeInAccruedExpense | 37.83K | -3.97K | -122.27K | 141.57K |
| ChangeInInterestPayable | 0.00 | 36.61K | ||
| ChangeInPayable | 921.22K | 35.47K | -526.73K | |
| ChangeInAccountPayable | 921.22K | 35.47K | 0.00 | -526.73K |
| StockBasedCompensation | 7.25M | 2.38M | 1.74M | 660.58K |
| DepreciationAmortizationDepletion | 3.61K | 3.61K | 3.61K | 3.61K |
| DepreciationAndAmortization | 3.61K | 3.61K | 3.61K | 3.61K |
| AmortizationCashFlow | 3.61K | 3.61K | 3.61K | 3.61K |
| AmortizationOfIntangibles | 3.61K | 3.61K | 3.61K | 3.61K |
| NetIncomeFromContinuingOperations | -15.79M | -8.89M | -7.83M | -4.57M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for GLSI
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|